Description of Invention:
The invention demonstrates that the approach of autoantibody analysis provides a valuable approach for cancer diagnosis. Detecting serum autoantibodies against extracellular form of protein kinase A (ECPKA) can effectively diagnose cancer.
The technology describes compositions and methods for detecting autoantibodies against an ECPKA for the diagnosis of cancer. Because ECPKA is secreted from cancer cells at higher rate than normal cells, the formation of serum autoantibodies to ECPKA in cancer patients is greater. A highly sensitive enzyme immunoassay that measures the presence of anti-ECPKA autoantibody in serum of of cancer patients can therefore be used for cancer diagnosis.
Application:
ECPKA-autoantibody-based immunoassay method provides an important diagnostic procedure applicable for the detection of various cancers.
Advantages:
Highly sensitive and specific immunoassay developed for anti-ECPKA antibody is more sensitive and specific than results from other current assays that detect only antigen activity
High statistical corelation betweeen the presence of serum-autoantibody directed against ECPKA and presence of cancer
Benefits:
Early detection of cancer and this technology can contribute significantly to improving the clinical management of cancer and thus the quality of life for people suffering from the disease. Furthermore, the cancer diagnostic market is estimated to grow to almost $ 10 billion dollars in the next 5 years, providing a significant financial opportunity.
Inventors:
Yoon S. Cho-Chung (NCI)
Patent Status:
DHHS Reference No. E-081-2004/2 --
U.S. Patent Application No. 10/592,040
Foreign Rights are also available
Portfolios: Cancer
Cancer -Diagnostics-In Vitro-MAb Based Cancer -Diagnostics-In Vivo-MAb Cancer -Diagnostics
For Additional Information Please Contact: David A. Lambertson Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-4632
Email: lambertsond@mail.nih.gov
Fax: (301) 402-0220
